8-K: Clearside Biomedical Reports Q4 and Full Year 2023 Results, Provides Corporate Update

Clearside Biomedical announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a strengthened financial position.

Summary

• Clearside Biomedical reported a net loss of $4.8 million for the fourth quarter of 2023, an improvement from a $9.7 million loss in the same period of 2022.
• The company's Q4 2023 revenue was $6.3 million, significantly up from $0.3 million in Q4 2022, primarily due to a $5.0 million upfront license fee from BioCryst and a $1.0 million milestone payment from Aura Biosciences.
• Research and development expenses for Q4 2023 were $6.3 million, compared to $5.0 million in Q4 2022, driven by costs associated with the ODYSSEY clinical trial.
• For the full year 2023, Clearside reported a net loss of $32.5 million, slightly better than the $32.9 million loss in 2022.
• Full year 2023 revenue was $8.2 million, up from $1.3 million in 2022, again driven by the BioCryst license and Aura Biosciences milestones.
• The company's cash and cash equivalents totaled $28.9 million as of December 31, 2023.
• A registered direct offering in February 2024 generated $15.0 million in gross proceeds, extending the company's cash runway into the third quarter of 2025.
• The Phase 2b ODYSSEY trial for CLS-AX in wet AMD remains on track, with topline data expected in the third quarter of 2024.
• Clearside's partners continue to report positive clinical data using the SCS Microinjector.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial results, successful fundraising, and progress in clinical trials. However, the company is still operating at a loss and faces risks associated with clinical development and reliance on partners.

Positives

• The company's revenue increased significantly due to licensing agreements and milestone payments.
• The net loss decreased compared to the same period last year.
• The company secured additional funding through a registered direct offering.
• The cash runway has been extended into the third quarter of 2025.
• The Phase 2b ODYSSEY trial is progressing as planned.
• Partners are reporting positive clinical data using Clearside's technology.
• Real-world data supports the extended treatment duration of XIPERE.

Negatives

• The company continues to operate at a loss.
• Research and development expenses increased due to the ODYSSEY clinical trial.
• Non-cash interest expense related to the sales of future royalties is significant.

Risks

• The company is reliant on the success of its clinical trials, particularly the ODYSSEY trial.
• The company depends on third-party partners for development and commercialization.
• There are inherent risks and uncertainties in the conduct of clinical trials.
• The company's future financial performance is dependent on the success of its products and partnerships.

Future Outlook

The company expects to report topline data from the ODYSSEY Phase 2b clinical trial in the third quarter of 2024 and believes its current cash reserves will fund operations into the third quarter of 2025.

Management Comments

• George Lasezkay, Pharm.D., J.D., Clearsides President and Chief Executive Officer, stated that this is an exciting time for Clearside with substantial progress in their TKI program and expanded use of their injection device technology.
• Dr. Lasezkay mentioned that they are laser focused on completing the ODYSSEY Phase 2b clinical trial and expect to report topline data in the third quarter of this year.
• Dr. Lasezkay highlighted the potential of CLS-AX to be a best-in-class product for long-term maintenance therapy for wet AMD patients.
• Dr. Lasezkay noted that the company's cash and cash equivalents will enable them to fund operations into the third quarter of 2025.

Industry Context

This announcement highlights the growing interest in suprachoroidal drug delivery for treating eye diseases, with Clearside positioning itself as a leader in this space. The positive data from partner programs using the SCS Microinjector further validates the technology's potential. The licensing agreement with BioCryst also indicates the increasing adoption of this delivery method by other pharmaceutical companies.

Comparison to Industry Standards

• Clearside's focus on suprachoroidal delivery is a differentiated approach compared to traditional intravitreal injections, which are the standard of care for many retinal diseases.
• The reported durability of XIPERE, with over 75% of eyes not requiring retreatment for 6 months, is a significant advantage compared to other treatments that require more frequent injections.
• The licensing agreement with BioCryst is similar to other deals in the biotech industry where companies leverage their proprietary technology for specific applications.
• The clinical trial progress of CLS-AX is comparable to other companies developing treatments for wet AMD, such as Regeneron's Eylea and Roche's Lucentis, but with a different delivery method.
• The positive data from REGENXBIO and Aura Biosciences using Clearside's technology is similar to other companies using gene therapy and other novel approaches to treat eye diseases.

Stakeholder Impact

• Shareholders will be encouraged by the improved financial results and progress in clinical trials.
• Employees will be reassured by the company's extended cash runway and continued development efforts.
• Patients may benefit from the potential of new treatments for eye diseases using Clearside's technology.
• Partners will be interested in the continued validation of the SCS Microinjector and its potential applications.

Next Steps

• Clearside will continue to advance the ODYSSEY Phase 2b clinical trial for CLS-AX.
• The company will work closely with BioCryst Pharmaceuticals on their program targeting diabetic macular edema (DME).
• Clearside will continue to present data on its suprachoroidal delivery platform at medical meetings.
• The company will monitor the progress of its partners' programs using the SCS Microinjector.

Key Dates

Keywords

suprachoroidal, SCS Microinjector, wet AMD, CLS-AX, XIPERE, clinical trial, BioCryst, ophthalmology, retina, axitinib, DME, licensing, biopharmaceutical